Results 1 to 10 of about 17,128 (260)

A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease

Frontiers in Immunology, 2023
IntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as an increasingly recognized problem among people living with HIV (PLWH).
Javier Martínez-Sanz, Javier Martínez-Sanz, Alba Talavera-Rodríguez, Alba Talavera-Rodríguez, Alba Talavera-Rodríguez, Jorge Díaz-Álvarez, Marta Rosas Cancio-Suárez, Marta Rosas Cancio-Suárez, Juan Miguel Rodríguez, Claudio Alba, María Luisa Montes, Rosa Martín-Mateos, Diego Burgos-Santamaría, Santiago Moreno, Santiago Moreno, Sergio Serrano-Villar, Sergio Serrano-Villar, Matilde Sánchez-Conde, Matilde Sánchez-Conde   +18 more
doaj   +1 more source

Complementary roles of Nutri-Score and NOVA in assessing pre-packaged food products available in Southeast Asia from an online food database [PDF]

Exploration of Foods and Foodomics
Aim: This study characterized pre-packaged foods in Southeast Asia using Nutri-Score, NOVA, and Multiple Traffic Light systems; cross-classified products by Nutri-Score and NOVA; and assessed their ability to discriminate products by nutrient content ...
Melvin Bernardino, Nicole Kate Sison, Ma. Theresa Alcantara, Claudio Tiribelli, Natalia Rosso   +4 more
doaj   +1 more source

DMF, an activator of Nrf2, could mitigate cholic-acid-induced liver damage in high-fat diet [PDF]

Exploration of Digestive Diseases
Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread chronic liver condition associated with liver inflammation, fibrosis, and various metabolic disorders.
Diana Abu-Halaka, Einat Rauchbach, Haim Zeigerman, Oren Tirosh   +3 more
doaj   +1 more source

Microbiota and metabolic dysfunction associated with steatotic liver disease [PDF]

Microbiota in Health and Disease
Disease progression in metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by multiple mechanisms that act together in genetically predisposed subjects. Amongst others, the gut-liver axis plays a crucial role in the development and
Q. Zhu, S. Francque, W. Kwanten
doaj   +1 more source

Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective [PDF]

Exploration of Drug Science
Metabolic dysfunction-associated steatohepatitis (MASH) is emerging as a leading cause of cirrhosis, hepatocellular carcinoma, and liver-related mortality worldwide.
Ralf Weiskirchen
doaj   +1 more source

Disparities in liver transplant waitlist characteristics and outcomes among Hispanic compared to non-Hispanic adults

Frontiers in Transplantation
BackgroundSocial determinants of health (SDOH) and transplant center characteristics have been associated with access to liver transplantation (LT) for Hispanic individuals. The aim of this study was to identify waitlist characteristics and correlates of
Monica Tincopa, Jordan L. Pace, Jordan L. Pace, Fanny Delebecque, Kelly Torosian, Denya Arellano, Maria Elena Martinez, Irine Vodkin, Veeral Ajmera   +8 more
doaj   +1 more source

Association of metabolic dysfunction-associated steatotic liver disease trajectories with incident liver cancer: a UK Biobank cohort study

Frontiers in Endocrinology
BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a contributor to hepatocellular carcinoma. Whether repeated assessment of MASLD provides additional prognostic information for liver cancer risk ...
Ryuk Jun Kwon, Ryuk Jun Kwon, Yohwan Lim, Yohwan Lim   +3 more
doaj   +1 more source

Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023 [PDF]

Clinical and Molecular Hepatology
Background/Aims Multi-society experts proposed the adoption of new terminology, metabolic dysfunction-associated steatotic liver disease (MASLD) and steatotic liver disease (SLD).
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed   +5 more
doaj   +1 more source

Factors associated with protection from MASLD in type 2 diabetes: A prospective study integrating longitudinal MRI/MRE and stable isotope tracing

JHEP Reports
Background & Aims: Type 2 diabetes is one of the strongest risk factors for the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD).
Federica Tavaglione, Veeral Ajmera, Luis Antonio Díaz, Kelvin Li, Egbert Madamba, Ricki Bettencourt, Lisa Richards, Marc Hellerstein, Rohit Loomba   +8 more
doaj   +1 more source

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease [PDF]

Clinical and Molecular Hepatology
In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring disease progression, predicting the development of liver ...
Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip   +6 more
doaj   +1 more source